97
LIFE-BTK - Clinical trial to evaluate the safety and effectiveness of the new Esprit below-the-knee ( BTK ) everolimus-eluting resorbable scaffold system . Principal investigator : Katherine Kane , MD .
OPTION – A study to determine if left atrial appendage closure with the WATCHMAN ® FLX device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high-risk patients with non-valvular atrial fibrillation . Principal investigator : Craig Delaughter , MD .
PACES - Anticoagulation for New-Onset Post- Operative Atrial Fibrillatiion after CABG ( PACeS ). Principal investigator : Anita Krueger , MD .
PARAGLIDE HF - A multi-center , randomized , double-blind , double-dummy , parallel group , active controlled study to evaluate the effect of sacubitril / valsarta ( LCZ696 ) versus valsartan on changes in NT-proBNP and outcomes , safety , and tolerability in HFpEF patients with acute decompensated heart failure ( ADHF ) who have been stabilized during hospitalization and initiated in-hospital or within 30 days post discharge . Principal investigator : Salman Gohar , MD .
PROACT XA - A prospective , randomized , active ( warfarin ) controlled , parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixan . Principal investigator : Anita Krueger , MD .
WAVECREST - A prospective , multi-center , randomized , active controlled , clinical trial of the Coherex WaveCrest ® Left Atrial Appendage Occlusion System compared to the Watchman ® LAA Closure Device for the reduction in risk of ischemic stroke or systemic embolism in subjects with nonvalvular atrial fibrillation that have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation . Patients are in followup . Principal investigator : Craig Delaughter , MD .
INTERNATIONALLY RECOGNIZED CARDIOVASCULAR LEADERS
Heart Failure Expert , Distinguished Scholar
Milton Packer , MD , distinguished scholar in Cardiovascular Science at Baylor Scott & White Heart and Vascular Institute , continued his leadership role in heart failure by serving as principal investigator for two ongoing national trials — one focused on heart failure and reduced ejection fraction , and the other that evaluated heart failure and preserved ejection fraction . He also led two new trials — one evaluating treatment of obesity-related heart failure with preserved ejection fraction and the second studying a new drug for the treatment of end-stage heart failure and reduced ejection fraction .
A recipient of the Hellenic Heart Failure Society Lifetime Achievement Award , Dr . Packer continued his award-winning work as an educator by authoring weekly blog posts on the widelyrespected physician news site , MedPage Today . Read by thousands of physicians , the blog received the coveted Jesse H . Neal Prize for Best Blog / Commentary . This past year , he joined respected cardiologists at Columbia University and the University of Lorraine , France , to launch a new annual international heart failure conference . He continues his professorship and faculty appointment at the Imperial College in London , UK .
Dr . Packer was the featured speaker at many conferences and venues in fiscal year 2022 , including :
• eSPACE CRM Cardiovascular Symposium , Jan . 2022 . Virtual .
• Heart Failure Association annual meeting , June 2021 . Virtual .
• European Society of Cardiology annual meeting , Aug . 2021 . Virtual and Sophia Antipolis , France .
• Heart Failure Society of America annual meeting , Sept . 2021 . Denver , Colorado .
• Karl Swedberg MD Honorary Lecture , Gothenburg Symposium on Heart Failure , Nov . 2021 . Gothenburg , Sweden .
• Philip Poole-Wilson Memorial Lecture , British Society of Heart Failure , Dec . 2021 . London , United Kingdom .
Baylor Scott & White Heart and Vascular Hospital | Clinical Trials and Research